Search

Search bills, members, committees and pages...

GENENTECH

69 federal lobbying filings, 2023 to 2026.

GENENTECH is a client on 69 federal lobbying filings, 2023 to 2026, reporting $3.3M across them. Biotechnology company Based in District of Columbia.

An LDA filing reports one registrant’s income from one client for everything they worked that quarter, so a total here is the sum of whole filings and never a price for one issue or one bill.


Firms

5 it has hired, by filings.

RegistrantFilingsReported
CAPITOL COUNSEL LLC14$720K
FARRAGUT PARTNERS LLP14$700K
FORBES-TATE14$700K
THE MCMANUS GROUP14$700K
RIVENDELL GROUP LLP13$510K

By year

Filings and what they reported, newest year first.

YearFilingsIncomeExpenses
20269$430K
202520$980K
202420$960K
202320$960K

Issues

The LDA issue codes the filings were filed under.

CodeIssueFilings
MMMMedicare/Medicaid68
HCRHealth Issues58
TAXTaxation/Internal Revenue Code27
BUDBudget/Appropriations14
CPTCopyright/Patent/Trademark14
MANManufacturing14

Bills

The bills the filings name, by how many name them.

BillTitleFilings
H.R. 4299Protecting Patient Access to Cancer and Complex Therapies Act5
H.R. 1492To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and bi…4
H.R. 1672Maintaining Investments in New Innovation Act1
H.R. 9504Tax Exempt Hospital Transparency Act1

Lobbyists

Named on the filings.

Filings

The documents themselves, on the Senate’s Lobbying Disclosure site, newest first.

ClientRegistrantPeriodReportedPosted
GENENTECHFORBES-TATE2026 second_quarter$50KJul 20, 2026
GENENTECHTHE MCMANUS GROUP2026 second_quarter$50KJul 20, 2026
GENENTECHFARRAGUT PARTNERS LLP2026 second_quarter$50KJul 20, 2026
GENENTECHCAPITOL COUNSEL LLC2026 second_quarter$50KJul 16, 2026
GENENTECHRIVENDELL GROUP LLP2026 first_quarter$30KApr 24, 2026
GENENTECHTHE MCMANUS GROUP2026 first_quarter$50KApr 20, 2026
GENENTECHFARRAGUT PARTNERS LLP2026 first_quarter$50KApr 20, 2026
GENENTECHCAPITOL COUNSEL LLC2026 first_quarter$50KApr 20, 2026
GENENTECHFORBES-TATE2026 first_quarter$50KApr 18, 2026
GENENTECHRIVENDELL GROUP LLP2025 fourth_quarter$40KJan 22, 2026
GENENTECHTHE MCMANUS GROUP2025 fourth_quarter$50KJan 20, 2026
GENENTECHFARRAGUT PARTNERS LLP2025 fourth_quarter$50KJan 20, 2026
GENENTECHCAPITOL COUNSEL LLC2025 fourth_quarter$50KJan 18, 2026
GENENTECHFORBES-TATE2025 fourth_quarter$50KJan 18, 2026
GENENTECHRIVENDELL GROUP LLP2025 third_quarter$40KOct 20, 2025
GENENTECHTHE MCMANUS GROUP2025 third_quarter$50KOct 20, 2025
GENENTECHFARRAGUT PARTNERS LLP2025 third_quarter$50KOct 20, 2025
GENENTECHFORBES-TATE2025 third_quarter$50KOct 18, 2025
GENENTECHCAPITOL COUNSEL LLC2025 third_quarter$50KOct 17, 2025
GENENTECHCAPITOL COUNSEL LLC2025 second_quarter$70KJul 22, 2025
GENENTECHTHE MCMANUS GROUP2025 second_quarter$50KJul 21, 2025
GENENTECHFARRAGUT PARTNERS LLP2025 second_quarter$50KJul 21, 2025
GENENTECHRIVENDELL GROUP LLP2025 second_quarter$40KJul 17, 2025
GENENTECHFORBES-TATE2025 second_quarter$50KJul 17, 2025
GENENTECHRIVENDELL GROUP LLP2025 first_quarter$40KApr 23, 2025